Opaleye Management Inc. Protagonist Therapeutics, Inc Transaction History
Opaleye Management Inc.
- $548 Million
- Q3 2024
A detailed history of Opaleye Management Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Opaleye Management Inc. holds 105,000 shares of PTGX stock, worth $4.27 Million. This represents 0.86% of its overall portfolio holdings.
Number of Shares
105,000
Previous 105,000
-0.0%
Holding current value
$4.27 Million
Previous $3.64 Million
29.69%
% of portfolio
0.86%
Previous 0.93%
Shares
8 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$238 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$234 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$221 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$172 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$130 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...